Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-cycloserine for GLDC Mutation Carriers
NCT02304432Phase 1Completed
- Sponsor
- McLean Hospital
- Start
- Sep 2015
- Primary completion
- Sep 2016
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of d-cycloserine in schizophrenia and bipolar disorder (BD) (3 arms), sponsored by McLean Hospital. Primary endpoints: Positive and Negative Symptom Scores at 24 weeks, Brief Psychiatric Rating Scale at 24 weeks and 3 more. Started Sep 2015; status: completed.
02
Drugs
d-cycloserine
03
Conditions
schizophreniabipolar disorder (BD)
Beyond the preview
Go deeper on NCT02304432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02304432.